Antibiotics in Dentistry: Mechanisms, Spectra, and Clinical Use

Core Review

Antibiotic Mechanisms: An Overview

Antibiotics are classified by their mechanism of action. The NBDHE expects you to know which mechanism each major class uses:

1. Cell wall synthesis inhibitors (BACTERICIDAL):

• Penicillins (amoxicillin, ampicillin, penicillin V)
• Cephalosporins (cephalexin, cefdinir, ceftriaxone)
• Vancomycin
• Bacitracin

These drugs disrupt peptidoglycan cross-linking in the bacterial cell wall → osmotic lysis. They are bactericidal because bacteria cannot survive without an intact cell wall. They are most effective against actively dividing (growing) bacteria.

2. Protein synthesis inhibitors (BACTERIOSTATIC or BACTERICIDAL depending on drug and organism):

• 30S ribosomal subunit: Tetracyclines (doxycycline, minocycline), aminoglycosides (gentamicin)
• 50S ribosomal subunit: Macrolides (erythromycin, azithromycin, clarithromycin), clindamycin, linezolid, chloramphenicol

These drugs bind to bacterial ribosomes (70S, composed of 30S + 50S subunits), inhibiting protein synthesis. Human ribosomes (80S) are structurally different, providing selective toxicity.

3. Nucleic acid synthesis inhibitors:

• Fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin): Inhibit DNA gyrase and topoisomerase IV → block DNA replication. BACTERICIDAL.
• Metronidazole: Reduced by bacterial nitroreductases → toxic metabolites cause DNA strand breaks. BACTERICIDAL. Specific for ANAEROBIC bacteria.

4. Antimetabolites (Folate synthesis inhibitors):

• Sulfonamides (sulfamethoxazole): Inhibit dihydropteroate synthase → block folate synthesis
• Trimethoprim: Inhibits dihydrofolate reductase → block folate reduction
• Sulfamethoxazole/Trimethoprim (Bactrim, Septra): Sequential folate blockade → synergistic bactericidal effect. BACTERIOSTATIC individually, BACTERICIDAL in combination.

5. Cell membrane disruptors:

• Polymyxins (polymyxin B, colistin): Disrupt Gram-negative outer membrane → leakage of cell contents. BACTERICIDAL.

Penicillins

Prototype: Amoxicillin. First-line for most odontogenic infections.

Mechanism: Bind to penicillin-binding proteins (PBPs, transpeptidases) → inhibit transpeptidation (cross-linking of peptidoglycan) → prevent cell wall synthesis → activation of autolysins → bacterial cell lysis.

Spectrum: Effective against Gram-positive cocci (Streptococcus, including many oral streptococci) and many oral anaerobes. Amoxicillin has better oral absorption than penicillin V.

Beta-lactamase (penicillinase) resistance: Many bacteria produce beta-lactamase enzymes that hydrolyze the beta-lactam ring, rendering the drug inactive. This is the most common mechanism of penicillin resistance.

• Amoxicillin-clavulanate (Augmentin): Amoxicillin + clavulanic acid (a beta-lactamase inhibitor). Clavulanic acid binds irreversibly to beta-lactamase, protecting the amoxicillin. This broadens the spectrum to include beta-lactamase-producing bacteria (e.g., Staphylococcus aureus, many oral anaerobes that produce beta-lactamases). Used for more severe or recurrent odontogenic infections.

Adverse effects:

• Hypersensitivity (allergy): Most common drug allergy. Ranges from mild rash to anaphylaxis. IgE-mediated (Type I) hypersensitivity → urticaria, angioedema, bronchospasm, hypotension, anaphylactic shock. Non-IgE maculopapular rash common with ampicillin/amoxicillin (especially when given during EBV infection — "ampicillin rash").
• GI: Nausea, diarrhea, C. difficile-associated diarrhea
• Cross-reactivity: Penicillin-allergic patients have a ~1-5% risk of cross-reactivity with cephalosporins (historically overstated; current data suggest lower risk, especially with 3rd-generation cephalosporins). Avoid cephalosporins in patients with a history of severe (anaphylactic) penicillin allergy.

Cephalosporins

Mechanism: Same as penicillins (cell wall synthesis inhibition via PBP binding).

Generations: Different generations have expanding Gram-negative coverage and decreasing Gram-positive coverage:

• 1st generation (cephalexin [Keflex]): Good Gram-positive, some Gram-negative. Use for skin/soft tissue infections; acceptable alternative for dental infections in non-anaphylactic penicillin-allergic patients.
• 2nd generation (cefuroxime): Broader Gram-negative
• 3rd generation (ceftriaxone, cefdinir): Expanded Gram-negative, crosses blood-brain barrier
• 4th/5th generation: Broadest spectrum, anti-Pseudomonal, anti-MRSA

Adverse effects: Similar to penicillins. No unique dental-specific adverse effects beyond allergy risk.

Macrolides

Prototype: Erythromycin. Newer: Azithromycin, Clarithromycin.

Mechanism: Bind to the 50S ribosomal subunit → inhibit translocation of peptidyl-tRNA → block protein synthesis. BACTERIOSTATIC.

Spectrum: Gram-positive cocci, atypical respiratory pathogens (Mycoplasma, Chlamydia, Legionella). Azithromycin has improved tolerability, longer half-life, and better tissue penetration than erythromycin.

Dental use: Alternative for penicillin-allergic patients (though clindamycin is often preferred for odontogenic infections). Azithromycin may be used for periodontitis in some protocols.

Adverse effects: GI intolerance (erythromycin — significant nausea, diarrhea, abdominal cramping; azithromycin is better tolerated). QT interval prolongation (risk of torsades de pointes). CYP3A4 inhibition → numerous drug interactions.

Clindamycin

A lincosamide antibiotic with particular importance in dentistry.

Mechanism: Binds to 50S ribosomal subunit (same binding site as macrolides) → inhibits protein synthesis. BACTERIOSTATIC (can be bactericidal at high concentrations against some organisms).

Spectrum: Excellent Gram-positive and ANAEROBIC coverage (both Gram-positive and Gram-negative anaerobes). Inactive against aerobic Gram-negative bacteria. Excellent activity against oral anaerobes (Peptostreptococcus, Prevotella, Fusobacterium, Porphyromonas, many Actinomyces).

Dental use: First-line alternative for penicillin-allergic patients with odontogenic infections. Excellent bone penetration.

Adverse effects:

• Clostridioides difficile colitis (pseudomembranous colitis): THE classic antibiotic associated with C. difficile infection. Clindamycin suppresses normal gut flora, allowing C. difficile overgrowth → production of toxins A and B → severe diarrhea, pseudomembranes on colonoscopy, toxic megacolon, death. Any antibiotic-associated diarrhea should raise concern, particularly with clindamycin.
• Metallic taste, GI upset
• Risk of C. difficile with any antibiotic, but classically associated with clindamycin, fluoroquinolones, and broad-spectrum penicillins/cephalosporins

Tetracyclines

Mechanism: Bind to 30S ribosomal subunit → inhibit tRNA binding to the A site → block protein synthesis. BACTERIOSTATIC.

Spectrum: Broad-spectrum; Gram-positive, Gram-negative, anaerobes, atypical bacteria (Rickettsia, Chlamydia, Mycoplasma), spirochetes. Doxycycline and minocycline are the most commonly used in dentistry.

Dental-specific uses:

• Periodontitis: Sub-antimicrobial dose doxycycline (Periostat — 20 mg BID) as a host-modulation therapy. At this low dose, doxycycline inhibits collagenase (MMP-8, MMP-9) without antimicrobial activity, reducing collagen breakdown in periodontitis. Do NOT confuse with antimicrobial-dose doxycycline.
• Minocycline: Used locally (Arestin — minocycline microspheres) for periodontal pocket placement as adjunctive therapy after scaling and root planing.
• *Aggressive periodontitis associated with A. actinomycetemcomitans:* Doxycycline 100 mg may be used as adjunctive systemic antibiotic therapy in certain protocols.

DENTAL ADVERSE EFFECT — TETRACYCLINE STAINING: Tetracyclines chelate calcium ions and are deposited in mineralizing tissues — BONE and DEVELOPING TEETH. If administered during tooth development (pregnancy, infancy, childhood up to approximately age 8-12 years), tetracyclines cause PERMANENT intrinsic tooth discoloration:

• Yellow-brown to gray-brown staining
• Band-like discoloration (corresponding to the period of drug exposure during tooth formation)
• Fluorescence under UV light
• Teeth may also exhibit enamel hypoplasia

CONTRAINDICATED in:

• Pregnant women (crosses placenta → stains developing fetal teeth)
• Children under 8-12 years (stains developing permanent teeth)
• Breastfeeding mothers (excreted in breast milk)

Doxycycline binds calcium less avidly than tetracycline and minocycline and may carry a lower staining risk, but caution is still warranted in children.

Other tetracycline adverse effects: Photosensitivity (especially doxycycline — sunburn risk), GI upset, esophageal ulceration (take with full glass of water, remain upright), vestibular toxicity (minocycline — dizziness, vertigo), hepatotoxicity. Not for use in renal failure (except doxycycline which has primarily GI elimination).

Metronidazole

Mechanism: Metronidazole is a prodrug that requires activation by bacterial nitroreductases under ANAEROBIC conditions. The reduced (active) metabolite causes DNA strand breaks and inhibits DNA synthesis. BACTERICIDAL.

Spectrum: UNIQUE — highly specific for ANAEROBIC bacteria (both Gram-positive and Gram-negative anaerobes). NO activity against aerobic or facultative bacteria. Excellent activity against periodontal anaerobes (P. gingivalis, P. intermedia, Fusobacterium, Peptostreptococcus, and other anaerobic Gram-negative rods). Also active against Entamoeba histolytica, Giardia lamblia, Trichomonas vaginalis.

Dental use: Combined with a penicillin (amoxicillin) for synergistic treatment of severe or refractory periodontitis. The combination covers both aerobic/facultative organisms (penicillin) and strict anaerobes (metronidazole). Sometimes combined with amoxicillin for aggressive periodontitis.

Adverse effects: Metallic taste (common), GI upset, dark/red-brown urine (from metabolite), peripheral neuropathy with prolonged use. Disulfiram-like reaction with alcohol — metronidazole inhibits aldehyde dehydrogenase → accumulation of acetaldehyde → flushing, nausea, vomiting, headache, tachycardia. Patients MUST avoid alcohol during and for 48-72 hours after completing metronidazole therapy.

Antibiotic Comparisons for Odontogenic Infections

Bactericidal vs. Bacteriostatic

Bactericidal: Kills bacteria directly. Required for infections in immunocompromised patients (endocarditis, neutropenia, meningitis) where the host immune system cannot clear the infection. Examples: Penicillins, cephalosporins, vancomycin, metronidazole, fluoroquinolones, aminoglycosides.

Bacteriostatic: Inhibits bacterial growth and replication, relying on the host immune system to clear the infection. Examples: Tetracyclines, macrolides, clindamycin, sulfonamides, trimethoprim.

Clinical note: The distinction is not absolute — some bacteriostatic agents can be bactericidal at high concentrations or against highly susceptible organisms, and in immunocompromised patients, bactericidal agents are preferred. For most odontogenic infections in immunocompetent patients, both bacteriostatic and bactericidal agents are effective.

Antibiotic Resistance

Key mechanisms of resistance that the NBDHE may test:

1. Enzymatic inactivation: Beta-lactamases → hydrolyze penicillins and cephalosporins
2. Target modification: Altered penicillin-binding proteins (MRSA — mecA gene encodes PBP2a with low affinity for beta-lactams)
3. Efflux pumps: Actively export antibiotic from bacterial cell (tetracycline resistance)
4. Decreased permeability: Porin mutations reduce antibiotic entry (Gram-negative resistance)
5. Bypass pathways: Bacteria use alternative metabolic pathways (sulfonamide resistance)

*MRSA (Methicillin-resistant Staphylococcus aureus):* Altered PBP (PBP2a via mecA gene) → resistant to ALL beta-lactams (penicillins, cephalosporins, carbapenems). Treatment: Vancomycin, linezolid, daptomycin, or newer anti-MRSA agents. Dental relevance: MRSA can cause facial cellulitis and odontogenic infections in hospitalized or healthcare-exposed patients.

Clinical Application

For most routine odontogenic infections (periapical abscess, localized dentoalveolar infection), antibiotic therapy is an ADJUNCT to definitive dental treatment (incision and drainage, root canal treatment, extraction), NOT a substitute. The source of infection must be addressed. Antibiotic choice follows principles: (1) narrowest effective spectrum, (2) lowest toxicity, (3) consideration of patient allergies and drug interactions, (4) appropriate dose and duration.

Common Traps

• Thinking metronidazole alone is adequate for odontogenic infections — it has NO aerobic coverage; odontogenic infections are mixed aerobic-anaerobic
• Confusing sub-antimicrobial doxycycline (Periostat, 20 mg BID) with antimicrobial doxycycline (100 mg BID) — different mechanisms, different indications
• Forgetting tetracycline contraindication in pregnancy and children
• Thinking all beta-lactam-allergic patients can take cephalosporins — cross-reactivity risk exists (~1-5%), especially with severe penicillin allergy
• Prescribing antibiotics without definitive dental treatment — antibiotics alone will NOT cure an odontogenic infection